Evidence map›Paper›PMID 37885887›Full record

Observational studyFrontiers in immunology2023

Kappa free light chains index in multiple sclerosis very long-term prognosis.

Pablo Arroyo-Pereiro, Lydia García-Serrano, Francisco Morandeira, Blanca Urban, Virginia Mas, Mario Framil, Isabel León, Albert Muñoz-Vendrell, Elisabet Matas, Lucía Romero-Pinel and 3 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Pablo Arroyo-PereiroMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Lydia García-SerranoDepartment of Immunology, Hospital Universitari de Bellvitge - Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Francisco MorandeiraDepartment of Immunology, Hospital Universitari de Bellvitge - Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Blanca UrbanDepartment of Immunology, Hospital Universitari de Bellvitge - Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Virginia MasDepartment of Immunology, Hospital Universitari de Bellvitge - Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Mario FramilDepartment of Immunology, Hospital Universitari de Bellvitge - Institut d'Investigació Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Isabel LeónMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Albert Muñoz-VendrellMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Elisabet MatasMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Lucía Romero-PinelMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Antonio Martínez-YélamosMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Sergio Martínez-YélamosMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Laura BauMultiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESBellvitge University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The role of the kappa-free light chain (kFLC) in the diagnosis of multiple sclerosis (MS) and, to a lesser extent, its role as a medium-term prognostic marker have been extensively studied. This study aimed to explore its potential as a long-term prognostic marker for MS. Methods: We performed an exploratory retrospective observational study by selecting patients systemically followed up in our MS unit with available cerebrospinal fluid and serum samples at the time of initial evaluation. Two groups were defined: benign MS (bMS), defined as patients with Expanded Disability Status Scale (EDSS) ≤ 3 at 10 years of follow-up, and aggressive MS (aMS), defined as patients with EDSS ≥ 6 at 15 years of follow-up. Clinical variables were collected, and the immunoglobulin G (IgG) index, kFLC index, and oligoclonal bands (OCB) were determined for all patients and compared between the groups. Results: Twenty bMS and 15 aMS patients were included in this study. Sixty percent (21/35) were female, and the mean age at the time of the first symptom was 31.5 ± 9.45 years, with no statistical differences between groups. Median follow-up time was 19.8 years (Interquartile range, IQR 15.9-24.6). The median EDSS scores at the last follow-up were 1.5 and 7.5 in the bMS and the aMS group, respectively. No statistically significant differences were found in the kFLC index between the two groups (136.6 vs. 140.27, p=0.59). The IgG index was positive in 62.9% of patients (55% bMS vs. 73.3% aMS, p>0.05), and OCB was positive in 88.6% (90% bMS vs. 86.7% aMS, p>0.05). A significant positive correlation was found between IgG and kFLC indices (r Conclusion: Given the absence of differences between the two groups with opposite disease courses, it is unlikely that the kFLC index is a reliable and powerful marker of long-term prognosis in MS.

Indexed as

Multiple SclerosisAdultFemaleHumansImmunoglobulin GImmunoglobulin kappa-ChainsMaleOligoclonal BandsPrognosisYoung AdultImmunoglobulin GImmunoglobulin kappa-ChainsOligoclonal Bandsbiomarkerscerebrospinal fluiddisabilitykappa free light chainslong-termmultiple sclerosisprognosis

Identifiers

PMID37885887
PMCPMC10598843
OpenAlexW4387532437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.